Oncology Medical News about Lymphoma, Large B-Cell, Diffuse

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Pazopanib Approved for Advanced Kidney Cancer

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Targeting Cancer Stem Cells: A New Therapeutic Initiative

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

New onset lymphopenia assessed during routine follow-up is a risk factor for relapse post-autologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma
Biology of Blood and Marrow Transplantation, 11/05/09

Porrata LF et al. – A specific predictor during routine follow–up to ascertain risk for post–APHSCT relapse in non–Hodgkin lymphoma (NHL) has not been identified. The authors studied if new onset lymphopenia measured by the absolute lymphocyte count (ALC) as a marker of post–APHSCT NHL relapse. This study suggests that new onset lymphopenia measured by ALC can be used as marker to assess risk of DLBCL relapse during routine follow–up for after APHSCT.

<< Previous
Endoprosthetic proximal femur replacement: Metastatic versus...

Next >>
Critical appraisal of temozolomide formulations in the treatment...